Zai Lab has a broad and validated late-stage pipeline in oncology, infectious disease and autoimmune. We currently have over 28 assets with 13 in late stage, 11 internally developed assets with global rights, 3 products commercialized in China and 5 products approved in the U.S. (marked with * below).

Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
No data!
Ovarian Cancer (1st line maintenance)*
China
Ovarian Cancer (2nd line maintenance) *
China
Gastric Cancer, Biliary Tract Cancer and Triple Negative Breast Cancer ( (I/O[3] combo)[1]
Other solid tumors[2] (I/O[3] combo)
Glioblastoma (GBM) *
China
Mesothelioma (MPM)*
NSCLC[4]
Brain Metastases from NSCLC
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer[1]
Liver Cancer
GIST[5] (4th Line)*
China
GIST[5] (2nd Line)
NSCLC, Colorectal Cancer (mono/combo)
B-NHL - r/r FL, r/r DLBCL, r/r MCL, r/r MZL [6, 7]
ROS1+ NSCLC[4], NTRK+[8] solid tumors
HER2+ Breast Cancer*
HER2+ Gastric/GEJ Cancer[9] (combo[10])
FGFR2b+ Gastric/GEJ Cancer[9]
EGFR ex20ins NSCLC
MET+ NSCLC and GC
Hepatocellular carcinoma (HCC)
Melanoma[1]
NSCLC[11]
MSI-High Endometrial Cancer[7]
Multiple tumor types
Multiple tumor types
Oncology
Oncology
Oncology
Oncology and autoimmune disease
No data!
No data!
Infectious Diseases
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
Carbapenem-Resistant Acinetobacter Infections
No data!
Neuroscience
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
Schizophrenia (Psychosis)
Schizophrenia (Psychosis in adults with an inadequate response to SOC)
Schizophrenia (Negative and cognitive symptoms)
Alzheimer's Disease Psychosis
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
Autoimmune Disorders
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
No data!
Generalized Myasthenia Gravis (gMG)
Immune Thrombocytopenic Purpura (ITP)
Pemphigus vulgaris (PV)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Myositis, Bullous Pemphigoid
Psoriasis

Note: [1]  China-only trials;  [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.